Email this article Creating a story on the pages of a book about diffuse B-large cell lymphoma
- Issue: Vol 24, No 2 (2022)
- Pages: 150-157
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/109358
- DOI: https://doi.org/10.26442/18151434.2022.2.201711
- ID: 109358
Cite item
Full Text
Abstract
Within the framework of VI All-Union Congress of Hematologists of Russia and III Congress of Transfusiologists of Russia, the symposium concerning diffuse large B cell lymphoma (DLBCL) was held on April 21. Leading Russian experts discussed current trends in diagnosis, the causes of the failures and successes of the treatment of this heterogeneous disease, the changes that are expected in the very near future. During the symposium, the detailed data concerning the new option for DLBCL therapy – polatuzumab vedotin (immunoconjugate) were also presented. The symposium was supported by Roche.
Full Text
##article.viewOnOriginalSite##Supplementary files
Supplementary Files
Action
1.
JATS XML
2.
Fig. 1. The structure of immunoconjugate. Antibody-linker-cytotoxic component.
Download (65KB)
3.
Fig. 2. Polatuzumab vedotin mechanism of action3 [8-12].
Download (169KB)
4.
Fig. 3. The GO29365 trial: the phase II study design [13].
Download (53KB)
5.
Fig. 4. The GO29365 trial: the impact of vedotin polatuzumab on PFS [13].
Download (141KB)
6.
Fig. 5. The GO29365 trial: the impact of vedotin polatuzumab on OS [13].
Download (147KB)
7.
Fig. 6. The GO29365 trial: the efficacy of therapy depending on the cellular origin of cancer [13].
Download (94KB)
8.
Fig. 7. The POLARIX trial: the study design [17].
Download (247KB)
9.
Fig. 8. The POLARIX trial: PFS according to the researchers [17].
Download (74KB)
